Evidence map›Paper›PMID 39007944›Full record

ArticleLung2024

Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry.

Femke Demolder, Eef Vanderhelst, Sylvia Verbanck, Florence Schleich, Renaud Louis, Guy Brusselle, Carine Sohy, Alain Michils, Rudi Peché, Charles Pilette and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Femke DemolderRespiratory Division, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), 1090, Brussels, Belgium. femke.demolder@uzbrussel.be.
Eef VanderhelstRespiratory Division, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), 1090, Brussels, Belgium.
Sylvia VerbanckRespiratory Division, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), 1090, Brussels, Belgium.
Florence SchleichRespiratory Medicine, CHU of Liège, University of Liège, GIGA I3, 4000, Liège, Belgium.
Renaud LouisDepartment of Pneumology, CHU Liège and GiGAI3 Research Group University of Liège, 4000, Liège, Belgium.
Guy BrusselleDepartment of Respiratory Medicine, Ghent University Hospital, 9000, Ghent, Belgium.
Carine SohyDepartment of Chest Medicine, Centre Hospitalier Universitaire UCL Namur (Site Godinne), Université Catholique de Louvain, Yvoir, Belgium.
Alain MichilsChest Department, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Rudi PechéCHU Charleroi Réseau Humani, ULB, Brussels, Belgium.
Charles PilettePneumology Department, Cliniques Universitaires Saint-Luc, and Institute of Experimental and Clinical Research (IREC), UCLouvain, 1200, Brussels, Belgium.
Shane HanonRespiratory Division, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), 1090, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNasal polyposis (NP) is a comorbidity of type 2 severe asthma (SA) which could influence response to SA biologics.

methodsWe evaluated (super-) response in SA patients with (NP +) and without NP (NP-) enrolled in the Belgian Severe Asthma Registry (BSAR).

results914 patients, of whom 31% NP + , were included. At enrollment, NP + patients had higher annual exacerbation rates, higher number of emergency room visits and more elevated type 2 biomarkers. In the longitudinal subanalysis of 104 patients, both groups had significant and similar asthma responses to asthma biologics, except for a greater increase in FEV

conclusionIn conclusion, both NP + and NP - patients had positive treatment responses, with some able to achieve super-response. In SA patients with NP, a greater FEV

Indexed as

AsthmaBiological ProductsNasal PolypsRegistriesAdultAgedAnti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedBelgiumFemaleForced Expiratory VolumeHumansMaleMiddle AgedOmalizumabSeverity of Illness IndexAnti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedbenralizumabBiological ProductsmepolizumabOmalizumabBiologicsNasal polyposisSevere asthmaSuper-response

Identifiers

PMID39007944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.